Navigation Links
Gladstone scientists uncover mechanism for the major genetic risk factor of Alzheimer's disease

SAN FRANCISCO, CAOCT. 13, 2010 -- Alzheimer's disease (AD) is an extremely complicated disease. Several proteins seem to be involved in its cause and progression. For example, the lipid-transport protein apolipoprotein E4 (apoE4) is the major genetic risk factor for AD, and apoE4 carriers account for 65󈞼% of all Alzheimer's cases, but exactly how apoE4 contributes to the disease is unclear.

Scientists at the Gladstone Institutes of Neurological Disease (GIND) have provided new insights into how apoE4 might be involved. In a study published today online in the Journal of Neuroscience, researchers led by led by Yadong Huang, MD, PhD, reported that apoE4-dependent learning and memory deficits are caused by loss of a specific type of neuron in the learning and memory center of the brain.

"We found that mice that had been genetically engineered to produce human apoE4 lost a specific kind of cells and that loss of these cells correlated with the extent of learning and memory deficits," said Yaisa Andrews-Zwilling, PhD, postdoctoral fellow and lead author of the study.

Those key cells are called GABAergic interneurons in the hilus of the hippocampus, an area of the brain involved in learning and memory and affected by AD. GABA is an important neurotransmitter released from GABAergic interneurons. As one component of a delicately balanced system for regulating brain activity, GABA functions to inhibit brain activity. AD brains seem to have low levels of GABA.

"Importantly, apoE4 causes GABAergic interneuron loss and learning and memory deficits in the absence of Ab peptide accumulation, a widely suspected toxin in Alzheimer's disease," said Dr. Huang, senior author of the study. "This demonstrates clearly that apoE4 plays Ab-independent roles in Alzheimer's disease."

To try to overcome the decrease of GABAergic interneuron function, the Gladstone team treated the apoE4 mice with daily injections of pentobarbital, a compound that enhances GABA action. They found that the injections rescued the learning and memory deficits in the mice. They also examined the effects of apoE4 on tau, another protein implicated in Alzheimer's disease. When they genetically eliminated the mouse's own tau, the loss of the GABAergic interneuron was halted and the learning and memory deficits were prevented.

"We previously showed that suppressing the protein tau can prevent Aβ from causing memory deficits and other abnormalities in mouse models of Alzheimer's disease," said Dr. Lennart Mucke, director of the Gladstone Institute of Neurological Disease. "This new study demonstrates that tau also acts downstream of apoE4. Thus, tau might be a general causative factor in Alzheimer's disease pathogenesis."

ApoE4 seems to increase the concentration of a particular species of tauphosphorylated tau known to be toxic in some kinds of neurodegeneration. Increases in the levels of phosphorylated tau eventually kill the GABAergic interneurons, and this loss leads to learning and memory deficits. The Gladstone team showed that giving the mice pentobarbital to boost the GABA function could stop this chain of events. In effect, they were providing a product of a reaction downstream from where apoE4 disrupts the pathway.

"Clinical studies have shown that apoE4 is associated with increased activity in the hippocampus at rest and in response to memory tasks in humans. Our study suggests that this may reflect the impaired GABAergic inhibitory neuronal functions in the presence of apoE4," said Dr. Huang. "Our study also demonstrates that increasing GABA signaling and reducing tau are potential strategies to treat or prevent apoE4-related Alzheimer's disease."


Contact: Valerie Tucker
Gladstone Institutes

Related biology news :

1. Gladstone scientists reveal that fat synthesizing enzyme is key to healthy skin and hair
2. Gladstone scientists reveal key enzyme in fat absorption
3. Gladstone scientists identify key factors in heart cell creation
4. Gladstones Shinya Yamanaka wins Lasker Award
5. Gladstone and Institute for Systems Biology collaborate on Huntingtons disease
6. Gladstones Shinya Yamanaka wins Kyoto prize
7. Gladstone scientists link hepatitis C virus infection to fat enzyme in liver cells
8. Jefferson scientists deliver toxic genes to effectively kill pancreatic cancer cells
9. Scientists identify novel inhibitor of human microRNA
10. Argonne scientists peer into heart of compound that may detect chemical, biological weapons
11. MU scientists go green with gold, distribute environmentally friendly nanoparticles
Post Your Comments:
(Date:3/31/2016)... -- Genomics firm Nabsys has completed a financial  restructuring under ... M.D., who returned to the company in October 2015. ... including Chief Technology Officer, John Oliver , Ph.D., ... Vice President of Software and Informatics, Michael Kaiser ... Bready served as CEO of Nabsys from 2005-2014 and ...
(Date:3/23/2016)... 2016 Einzigartige ... und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler Kommunikationsdienste, ... SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie einzusetzen. ... Möglichkeit angeboten, im Rahmen mobiler Apps neben ...
(Date:3/22/2016)... PROVO and SANDY, ... Screening Ontario (NSO), which operates the highest sample volume ... testing, and Tute Genomics and UNIConnect, leaders in clinical ... today announced the launch of a project to establish ... testing panel. NSO has been contracted ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... ... 23, 2016 , ... Mosio, a leader in clinical research ... Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the ... tools, and strategies for clinical researchers. , “The landscape of how patients receive ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and Mold) microbial test has received AOAC Research Institute approval 061601. , “This ... introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. ...
Breaking Biology Technology: